Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695111 | 0.88 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL15243760 | 0.88 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL10146890 | 0.88 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL14923714 | 0.82 | CA1 (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL18681164 | 0.81 | L3MBTL1 (0.41) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL19104593 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL14357345 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL15663302 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL7803484 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL25166100 | 0.80 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | CYP1A2 4529/4885CYP2C9 4647/4885CYP2C19 4597/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | CYP1A2 4095/4885CYP2C9 4062/4885CYP2C19 3721/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CYP1A2 4095/4885CYP2C9 4062/4885CYP2C19 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.